These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 29194460)

  • 41. Cellular alloreactivity of human cord blood cells detected by T-cell frequency analysis and a human skin explant model.
    Wang XN; Sviland L; Ademokun AJ; Dunn J; Cavanagh G; Proctor SJ; Dickinson AM
    Transplantation; 1998 Oct; 66(7):903-9. PubMed ID: 9798701
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induction of alloantigen-specific anergy in human peripheral blood mononuclear cells by alloantigen stimulation with co-stimulatory signal blockade.
    Davies JK; Barbon CM; Voskertchian AR; Nadler LM; Guinan EC
    J Vis Exp; 2011 Mar; (49):. PubMed ID: 21445041
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse.
    Weisdorf DJ; Nelson G; Lee SJ; Haagenson M; Spellman S; Antin JH; Bolwell B; Cahn JY; Cervantes F; Copelan E; Gale R; Gratwohl A; Khoury HJ; McCarthy P; Marks DI; Szer J; Woolfrey A; Cortes-Franco J; Horowitz MM; Arora M;
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1475-8. PubMed ID: 19822308
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease.
    Martin PJ; Levine DM; Storer BE; Warren EH; Zheng X; Nelson SC; Smith AG; Mortensen BK; Hansen JA
    Blood; 2017 Feb; 129(6):791-798. PubMed ID: 27872059
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells.
    Quach DH; Becerra-Dominguez L; Rouce RH; Rooney CM
    J Transl Med; 2019 Jul; 17(1):240. PubMed ID: 31340822
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alloreactive T Cells to Identify Risk HLA Alleles for Retransplantation After Acute Accelerated Steroid-Resistant Rejection.
    Leyking S; Wolf M; Mihm J; Schaefer M; Bohle RM; Fliser D; Sester M; Sester U
    Transplant Proc; 2015 Oct; 47(8):2425-32. PubMed ID: 26518945
    [TBL] [Abstract][Full Text] [Related]  

  • 47. T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome.
    Weisdorf D; Cooley S; Devine S; Fehniger TA; DiPersio J; Anasetti C; Waller EK; Porter D; Farag S; Drobyski W; Defor T; Haagenson M; Curtsinger J; Miller J
    Biol Blood Marrow Transplant; 2012 Jun; 18(6):937-43. PubMed ID: 22155505
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Third-party-mediated graft rejection and graft-versus-host disease after T-cell-depleted bone marrow transplantation, as demonstrated by hypervariable DNA probes and HLA-DR polymorphism.
    Drobyski W; Thibodeau S; Truitt RL; Baxter-Lowe LA; Gorski J; Jenkins R; Gottschall J; Ash RC
    Blood; 1989 Nov; 74(6):2285-94. PubMed ID: 2572285
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses.
    Amrolia PJ; Muccioli-Casadei G; Yvon E; Huls H; Sili U; Wieder ED; Bollard C; Michalek J; Ghetie V; Heslop HE; Molldrem JJ; Rooney CM; Schlinder J; Vitetta E; Brenner MK
    Blood; 2003 Sep; 102(6):2292-9. PubMed ID: 12763937
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alloreactive T Cell Receptor Diversity against Structurally Similar or Dissimilar HLA-DP Antigens Assessed by Deep Sequencing.
    Arrieta-Bolaños E; Crivello P; Metzing M; Meurer T; Ahci M; Rytlewski J; Vignali M; Yusko E; van Balen P; Horn PA; Falkenburg JHF; Fleischhauer K
    Front Immunol; 2018; 9():280. PubMed ID: 29520276
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation.
    Holler E; Rogler G; Herfarth H; Brenmoehl J; Wild PJ; Hahn J; Eissner G; Schölmerich J; Andreesen R
    Blood; 2004 Aug; 104(3):889-94. PubMed ID: 15090455
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Alloimmune T cells in transplantation.
    DeWolf S; Sykes M
    J Clin Invest; 2017 Jun; 127(7):2473-2481. PubMed ID: 28628037
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increased donor inhibitory KIR with known HLA interactions provide protection from relapse following HLA matched unrelated donor HCT for AML.
    Krieger E; Qayyum R; Keating A; Toor A
    Bone Marrow Transplant; 2021 Nov; 56(11):2714-2722. PubMed ID: 34234295
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Three-dimensional structure discrepancy between HLA alleles for effective prediction of aGVHD severity and optimal selection of recipient-donor pairs: a proof-of-concept study.
    Han H; Yuan F; Sun Y; Liu J; Liu S; Luo Y; Liang F; Liu N; Long J; Zhao X; Kong F; Xi Y
    Oncotarget; 2015 Nov; 6(37):40337-59. PubMed ID: 26498683
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Permissive HLA-DPB1 mismatches in HCT depend on immunopeptidome divergence and editing by HLA-DM.
    Meurer T; Crivello P; Metzing M; Kester M; Megger DA; Chen W; van Veelen PA; van Balen P; Westendorf AM; Homa G; Layer SE; Turki AT; Griffioen M; Horn PA; Sitek B; Beelen DW; Falkenburg JHF; Arrieta-Bolaños E; Fleischhauer K
    Blood; 2021 Feb; 137(7):923-928. PubMed ID: 33025005
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Collateral damage of nonhematopoietic tissue by hematopoiesis-specific T cells results in graft-versus-host disease during an ongoing profound graft-versus-leukemia reaction.
    van der Zouwen B; Kruisselbrink AB; Frederik Falkenburg JH; Jedema I
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):760-9. PubMed ID: 24607556
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Donor/Recipient HLA Molecular Mismatch Scores Predict Primary Humoral and Cellular Alloimmunity in Kidney Transplantation.
    Meneghini M; Crespo E; Niemann M; Torija A; Lloberas N; Pernin V; Fontova P; Melilli E; Favà A; Montero N; Manonelles A; Cruzado JM; Palou E; Martorell J; Grinyó JM; Bestard O
    Front Immunol; 2020; 11():623276. PubMed ID: 33776988
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CTL clones isolated from an HLA-Cw-mismatched bone marrow transplant recipient with acute graft-versus-host disease.
    Sugimoto K; Murata M; Terakura S; Naoe T
    J Immunol; 2009 Nov; 183(9):5991-8. PubMed ID: 19812210
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies.
    Baker M; Wang H; Rowley SD; Cai L; Pecora AL; Skarbnik A; Vesole DH; Adler-Brecher B; Kim D; Donato ML
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):2047-2055. PubMed ID: 27522040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.